VistaGen Therapeutics (NASDAQ:VTGN – Get Free Report) and Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, institutional ownership and profitability.
Insider and Institutional Ownership
78.4% of VistaGen Therapeutics shares are held by institutional investors. 2.9% of VistaGen Therapeutics shares are held by company insiders. Comparatively, 5.2% of Celldex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Volatility and Risk
VistaGen Therapeutics has a beta of 0.33, indicating that its stock price is 67% less volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500.
Profitability
This table compares VistaGen Therapeutics and Celldex Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| VistaGen Therapeutics | -2,702.64% | -152.59% | -117.45% |
| Celldex Therapeutics | N/A | -52.35% | -47.61% |
Analyst Ratings
This is a summary of current ratings and recommmendations for VistaGen Therapeutics and Celldex Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| VistaGen Therapeutics | 1 | 4 | 0 | 0 | 1.80 |
| Celldex Therapeutics | 1 | 1 | 11 | 0 | 2.77 |
VistaGen Therapeutics currently has a consensus price target of $0.95, suggesting a potential upside of 390.70%. Celldex Therapeutics has a consensus price target of $63.08, suggesting a potential upside of 114.79%. Given VistaGen Therapeutics’ higher probable upside, equities research analysts plainly believe VistaGen Therapeutics is more favorable than Celldex Therapeutics.
Earnings & Valuation
This table compares VistaGen Therapeutics and Celldex Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| VistaGen Therapeutics | $1.27 million | 6.77 | -$69.68 million | ($1.66) | -0.12 |
| Celldex Therapeutics | $1.54 million | 1,497.68 | -$258.76 million | ($4.35) | -6.75 |
VistaGen Therapeutics has higher earnings, but lower revenue than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Celldex Therapeutics beats VistaGen Therapeutics on 9 of the 13 factors compared between the two stocks.
About VistaGen Therapeutics
Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.
About Celldex Therapeutics
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company’s clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Receive News & Ratings for VistaGen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VistaGen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
